Germany-based Affimed NV has appointed Wolfgang Fischer as its chief operating officer to help oversee clinical development of the company’s immunotherapies for cancer. Dr Fischer joins from the Novartis business unit Sandoz where, since 2012, he has managed the development and registration of biosimilar medicines. He was previously medical director for oncology at Novartis Pharma Switzerland AG.
Dr Fischer holds a PhD in cancer research from the Swiss Federal Institute of Technology in Zurich.
Affimed announced the appointment on 13 September 2017.
Copyright 2017 Evernow Publishing Ltd